Retatrutide Results: What Phase 2 Data Shows About Weight Loss Timeline and Outcomes

The 2023 NEJM Phase 2 trial (NCT04881760, PMID 37352392) is the primary published source for retatrutide outcome data. 338 adults with obesity (BMI 27-50, HbA1c under 10% if diabetic) were randomized across five active dose groups plus placebo for 48 weeks. Here is what each group showed:

All between-group differences versus placebo were statistically significant (p less than 0.001). The 26.5% of 12 mg participants who lost 30% or more of their body weight represents a result that was previously considered achievable only through bariatric surgery.

The weight loss trajectory from the Phase 2 trial tells a specific story about when results occur. Published data and the dose-escalation schedule provide the following timeline picture:

Weeks 1-12: This is the dose escalation period for higher-dose groups. The 12 mg group starts at 2 mg and escalates over 12-16 weeks to reach maintenance dose. Weight loss begins immediately but reflects sub-maintenance dosing for the first several weeks.

Weeks 12-24: Most participants in higher-dose groups reach maintenance dose in this window. The weight loss rate accelerates noticeably as full triple receptor agonism is achieved. Published week-24 data shows approximately 15-17% weight loss in the 12 mg group, meaning roughly two-thirds of the 48-week result is achieved in the first six months.

Weeks 24-48: The final third of weight loss occurs in this window, and critically, the weight loss curves in the 8 mg and 12 mg groups had not plateaued at week 48. The curves were still declining at the trial’s end. This is different from semaglutide and tirzepatide, where curves begin flattening around weeks 52-68. The absence of a plateau is likely attributable to the glucagon receptor’s thermogenic contribution compounding over time.

Implication for Phase 3: The TRIUMPH Phase 3 program (currently enrolling) extends treatment to 72 weeks. If the trajectory continued after week 48, Phase 3 mean weight loss may exceed the 24.2% Phase 2 peak.

Comparing results across the three generations of incretin-based compounds requires acknowledging that these are not head-to-head trials. Different populations, different durations, different escalation schedules. That said, the published data paints a clear picture:

The progression is clear: each additional receptor (GIP added by tirzepatide, glucagon added by retatrutide) adds roughly 5-6 percentage points of weight loss in the published data. The absence of a plateau in retatrutide’s 48-week data is the most notable feature suggesting the final number may move further as Phase 3 data matures.

Weight loss numbers are the headline, but the metabolic improvements documented in the Phase 2 trial are arguably more significant from a health research perspective.

Blood glucose: Fasting glucose and HbA1c improved significantly in all dose groups, including in the participants without diabetes. The triple receptor mechanism drives glucose lowering through GLP-1 mediated insulin secretion, GIP receptor sensitization, and glucagon receptor-mediated hepatic glucose regulation simultaneously.

Lipids: Triglycerides fell substantially in higher-dose groups, with some participants showing reductions exceeding 50% from baseline. LDL-C showed modest reductions. These lipid improvements exceeded what would be expected from weight loss alone, suggesting direct metabolic effects of the triple agonism on lipid metabolism.

Blood pressure: Both systolic and diastolic blood pressure improved dose-dependently, consistent with the published cardiovascular effects of GLP-1 class drugs and the additional glucagon receptor effects on vascular tone.

Waist circumference: Reductions were proportional to weight loss, with higher-dose groups showing 15-20 cm reductions in waist circumference at 48 weeks, reflecting primarily visceral and subcutaneous abdominal fat loss.

Understanding the tolerability data matters as much as the efficacy data for research protocol design. The Phase 2 trial provides the most systematic published side effect profile available for retatrutide.

GI effects were the dominant tolerability issue across all dose groups: - Nausea: 42-60% in active groups vs 20% placebo - Vomiting: 12-27% in active groups vs 6% placebo - Diarrhea: 14-18% in active groups vs 11% placebo - Constipation: 10-17% in active groups vs 6% placebo

These rates are broadly consistent with other GLP-1 agonists, though rates trended higher at the highest doses. Critically, most GI events were rated mild to moderate and occurred predominantly during dose escalation. Once maintenance dose was established, GI event rates dropped substantially.

Discontinuation due to adverse events: 6.6% (4 mg), 11.8% (8 mg), 16.4% (12 mg). Heart rate increased modestly by 4-6 bpm across dose groups, consistent with glucagon receptor activity.

On hair loss: This is a commonly asked question. Telogen effluvium (temporary hair shedding) is a known side effect of rapid weight loss itself, not a specific property of retatrutide. It has been reported with semaglutide and tirzepatide for the same reason and resolves as weight stabilizes. No retatrutide-specific hair toxicity was identified in Phase 2 data.

For preclinical researchers studying metabolic biology, the Phase 2 data provides the most precise published characterization of retatrutide’s pharmacological effects and a clear dose-response architecture for protocol design.

The 1 mg dose group’s 8.7% weight loss is notable: it represents the GLP-1 receptor contribution without the amplifying effect of higher doses, providing a useful mechanistic reference point. The dose-response between 2 mg and 12 mg shows diminishing returns in terms of percentage points per mg, which is consistent with receptor saturation dynamics.

For researchers who want to study the glucagon receptor contribution specifically, comparing tirzepatide-class dual agonism outcomes to retatrutide triple agonism outcomes in parallel preclinical arms isolates that contribution. The approximately 3-5 percentage point difference in weight loss between tirzepatide (21%) and retatrutide (24%) represents the glucagon receptor’s incremental contribution.

Retatrutide is available for preclinical and in vitro research through Blackwell BioLabs at 99% purity. It is not approved for human therapeutic use.